Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian cancer. The main objective is to test whether the therapeutic intervention benefits the patient evaluating the number of subjects who are progression-free after 18 months from the beginning of the first line treatment.
Ovarian Cancer
DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin
Proportion of patients free from progression, 18 months from beginning of first line treatment
progression free survival, 3 years|overall survival, 5 years|number of patients with complete and partial responses, 18 months|worst grade toxicity per patient, according to Common Toxicity Criteria for Adverse Events v. 4.03, evaluated every 3 weeks up to 18 months|changes in patient-reported outcome (PRO) scores of disease-related symptoms from baseline, up to 18 months
This study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian cancer. The main objective is to test whether the therapeutic intervention benefits the patient evaluating the number of subjects who are progression-free after 18 months from the beginning of the first line treatment.